# IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

> **NCT01409174** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Temozolomide
- **DRUG:** Cisplatin
- **DRUG:** Interferon Alfa-2b
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT01409174
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-02
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Slow accrual, closed in Phase I.
- **Last updated:** 2017-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01409174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01409174, "IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01409174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*